Aligos Therapeutics (ALGS) Current Assets (2019 - 2026)

Aligos Therapeutics (ALGS) has reported Current Assets for 8 consecutive years, with $62.1 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Current Assets fell 51.44% year-over-year to $62.1 million; the trailing twelve-month figure through Jun 2026 stood at $62.1 million (down 51.44% YoY), and the FY2025 full-year result was $82.9 million, up 33.35% from the prior year.
• Current Assets climbed to $62.1 million in Q2 2026 per ALGS's latest filing, from $59.6 million in the prior quarter.
• Across five years, Current Assets topped out at $195.1 million in Q1 2022 and bottomed at $59.6 million in Q1 2026.
• Historically, Current Assets has averaged $111.4 million across 5 years, with a median of $106.4 million in 2023.
• The sharpest annual moves came in 2025 and 2026: Current Assets surged 33.35% in 2025, then tumbled 58.36% in 2026.
• Over 5 years, Current Assets stood at $133.5 million in 2022, then increased by 5.65% to $141.1 million in 2023, then plunged by 55.95% to $62.1 million in 2024, then jumped by 33.35% to $82.9 million in 2025, then decreased by 25.02% to $62.1 million in 2026.
• According to Business Quant data, Current Assets over the past three periods registered $62.1 million, $59.6 million, and $82.9 million for Q2 2026, Q1 2026, and Q4 2025 respectively.